Content area
Full Text
Intensive Care Med (2016) 42:333341DOI 10.1007/s00134-015-4071-z ORIGINAL
http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = http://crossmark.crossref.org/dialog/?doi=10.1007/s00134-015-4071-z&domain=pdf
Web End = David S. Y. OngCristian SpitoniPeter M. C. Klein Klouwenberg Frans M. Verduyn LunelJos F. FrenckenMarcus J. SchultzTom van der PollJozef KeseciogluMarc J. M. BontenOlaf L. Cremer
Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Received: 14 July 2015Accepted: 12 September 2015 Published online: 28 September 2015 The Author(s) 2015. This article is published with open access at Springerlink.com
Take-home message: CMV-seropositive critically ill patients with ARDS who remain mechanically ventilated for more than 4 days have a 27 % cumulative risk of developing CMV reactivation while in the ICU. Despite extensive statistical correction to account for time-varying aspects of exposure, competing risks, and the presence of confounding by differences in the evolution of disease severity prior to viremia onset, CMV reactivation remains independently associated with increased case fatality. The absolute mortality due to these reactivations is estimated at 4.4 % (95 % CI 1.17.9) by day 30.
On behalf of the MARS consortium. The members of the MARS consortium are given in the Appendix.
Electronic supplementary materialThe online version of this article (doi:http://dx.doi.org/10.1007/s00134-015-4071-z
Web End =10.1007/s00134-015-4071-z ) contains supplementary material, which is available to authorized users.
D. S. Y. Ong ())
P. M. C. Klein Klouwenberg
F. M. Verduyn Lunel M. J. M. Bonten
Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlandse-mail: [email protected].: ?31 88 756 1124
D. S. Y. Ong P. M. C. Klein Klouwenberg
J. F. Frencken J. Kesecioglu O. L. Cremer
Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
D. S. Y. Ong C. Spitoni
P. M. C. Klein Klouwenberg
J. F. Frencken M. J. M. Bonten
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
C. SpitoniDepartment of Mathematics, Utrecht University, Utrecht, The Netherlands
M. J. SchultzDepartment of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
T. van der PollCenter of Experimental and Molecular Medicine and Division of Infectious Diseases, Academic Medical Center, University of...